Phase II trial of edatrexate plus carboplatin in metastatic non-small- cell lung cancer: A Southwest Oncology Group study

Medicine and Dentistry

• Patient 100%
• Oncology 100%
• Non Small Cell Lung Cancer 100%
• Carboplatin 100%
• Phase II Trials 100%
• Mucositis 33%
• Toxicity 22%
• Bone Marrow Suppression 22%
• Sepsis 22%
• Cryotherapy 22%
• Therapeutic Procedure 11%
• Combination Therapy 11%
• Death 11%
• Disease 11%
• Survival 11%
• Patient Population 11%
• Neutropenia 11%
• Pleura Effusion 11%
• Aptitude 11%
• Treatment of Non-Small Cell Lung Cancer 11%
• Drug Dose Regimen 11%
• Median Survival Time 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Carboplatin 100%
• Edatrexate 100%
• Mucosa Inflammation 50%
• Toxicity 33%
• Sepsis 33%
• Ice 33%
• Bone Marrow Suppression 33%
• Death 16%
• Diseases 16%
• Survival 16%
• Tolerability 16%
• Neutropenia 16%
• Pleura Effusion 16%
• Phase I Trials 16%
• Preclinical Study 16%
• Median Survival Time 16%

Nursing and Health Professions

• Edatrexate 100%
• Mucosa Inflammation 33%
• Bone Marrow Suppression 22%
• Cryotherapy 22%
• Ice 22%
• Drug Dose Regimen 11%
• Preclinical Study 11%